journal article·2022-09-28

p53 Promotes Ferroptosis in Macrophages Treated with Fe3O4 Nanoparticles

Cong Wu, Zhiming Shen, Yi Lu, Fei Sun, Hongcan Shi

ACS Applied Materials & Interfaces· Volume 14· Issue 38
Publisher page

Abstract

Fe3O4 nanoparticles are the most widely used magnetic nanoparticles in the biomedicine field. The biodistribution of most nanoparticles in vivo is determined by the capture of macrophages; however, the effects of nanoparticles on macrophages remain poorly understood. Here, we demonstrated that Fe3O4 nanoparticles could reduce macrophage viability after 48 h of treatment and induce a shift in macrophage polarization toward the M1 phenotype; RNA sequencing revealed the activation of the ferroptosis pathway and p53 upregulation compared to the control group. The expression in p53, xCT, glutathione peroxidase 4 (GPX4), and transferrin receptor (TFR) in macrophages was similar to that in erastin-induced ferroptosis in macrophages, and the ultrastructural morphology of mitochondria was consistent with that of erastin-treated cells. We used DCFH-DA to estimate the intracellular reactive oxygen species content in Fe3O4 nanoparticles treated with Ana-1 and JC-1 fluorescent probes to detect the mitochondrial membrane potential change; both showed to be time-dependent. Fer-1 inhibited the reduction of the glutathione/oxidized glutathione (GSH/GSSG) ratio and inhibited intracellular oxidative stress states; therefore, Fe3O4 nanoparticles induced ferroptosis in macrophages. Finally, we used pifithrin-α hydrobromide (PFT) as a p53 inhibitor to verify whether the high expression of p53 is involved in mediating this process. After PFT treatment, the live/dead cell rate, TFR, p53 expression, and GPX4 consumption were inhibited and mitigated the GSH/GSSG ratio reduction as well. This indicates that p53 may contribute to Fe3O4 nanoparticle-induced ferroptosis of macrophages. We provide a theoretical basis for the molecular mechanisms of ferroptosis in macrophages and the biotoxicity in vivo induced by Fe3O4 nanoparticles.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Ferroptosis and cancer prognosis · Immune cells in cancer · Epigenetics and DNA Methylation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Clinical Medical College, Yangzhou University, Yangzhou 225000, China

Institute of Translational Medicine, Medical College, Yangzhou University, Yangzhou 225000, China

Jiangsu Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Treatment of Senile Diseases, Yangzhou University, Yangzhou 225000, China

Funding

National Natural Science Foundation of China

References (83)

Show source-provided references
1. 10.3390/ma1102032410.3390/ma11020324 ↗
2. 10.1016/j.saa.2016.08.04710.1016/j.saa.2016.08.047 ↗
3. 10.1016/j.molliq.2016.09.10310.1016/j.molliq.2016.09.103 ↗
4. 10.1021/acsami.6b1037010.1021/acsami.6b10370 ↗
5. 10.1021/acsami.7b0048110.1021/acsami.7b00481 ↗
6. 10.1021/acsami.6b1648610.1021/acsami.6b16486 ↗
7. 10.1021/acs.biomac.6b0188510.1021/acs.biomac.6b01885 ↗
8. 10.1038/nnano.2016.16810.1038/nnano.2016.168 ↗
9. 10.1038/s41577-019-0127-610.1038/s41577-019-0127-6 ↗
10. 10.1158/0008-5472.CAN-15-173710.1158/0008-5472.CAN-15-1737 ↗
11. 10.1016/j.phrs.2017.05.01010.1016/j.phrs.2017.05.010 ↗
12. 10.1080/17435390.2019.157280910.1080/17435390.2019.1572809 ↗
13. 10.1016/j.cell.2012.03.04210.1016/j.cell.2012.03.042 ↗
14. 10.1038/ncb306410.1038/ncb3064 ↗
15. 10.21037/tlcr-20-34110.21037/tlcr-20-341 ↗
16. 10.1038/s41422-019-0164-510.1038/s41422-019-0164-5 ↗
17. 10.1186/s12951-020-00700-810.1186/s12951-020-00700-8 ↗
18. 10.1016/j.biomaterials.2020.12053010.1016/j.biomaterials.2020.120530 ↗
19. 10.2147/IJN.S28248910.2147/IJN.S282489 ↗
20. 10.1111/jcmm.1572210.1111/jcmm.15722 ↗
21. 10.1016/j.freeradbiomed.2018.09.01410.1016/j.freeradbiomed.2018.09.014 ↗
22. 10.7554/eLife.0252310.7554/eLife.02523 ↗
23. 10.1038/nature1434410.1038/nature14344 ↗
24. 10.1016/j.freeradbiomed.2018.05.07410.1016/j.freeradbiomed.2018.05.074 ↗
25. 10.18632/aging.10130610.18632/aging.101306 ↗
26. 10.1016/j.celrep.2016.09.02210.1016/j.celrep.2016.09.022 ↗
27. 10.1021/acs.jproteome.5b0077010.1021/acs.jproteome.5b00770 ↗
28. 10.1038/nature1349010.1038/nature13490 ↗
29. 10.1021/acs.nanolett.8b0068910.1021/acs.nanolett.8b00689 ↗
30. 10.1128/iai.62.4.1199-1206.199410.1128/iai.62.4.1199-1206.1994 ↗
31. 10.1093/jnci/81.19.149210.1093/jnci/81.19.1492 ↗
32. 10.1016/j.it.2011.03.00710.1016/j.it.2011.03.007 ↗
33. 10.1016/j.cellimm.2014.05.01510.1016/j.cellimm.2014.05.015 ↗
34. 10.1016/j.celrep.2020.02.04910.1016/j.celrep.2020.02.049 ↗
35. 10.1039/C9BM00653B10.1039/C9BM00653B ↗
36. 10.3389/fendo.2018.0012410.3389/fendo.2018.00124 ↗
37. 10.3892/or.2018.658510.3892/or.2018.6585 ↗
38. 10.1111/cas.1338010.1111/cas.13380 ↗
39. 10.1016/j.semcancer.2019.03.00210.1016/j.semcancer.2019.03.002 ↗
40. 10.1016/j.foodchem.2020.12826310.1016/j.foodchem.2020.128263 ↗
41. 10.1038/nrm373710.1038/nrm3737 ↗
42. 10.1111/jcmm.1505310.1111/jcmm.15053 ↗
43. 10.1038/ncomms326610.1038/ncomms3266 ↗
44. 10.1021/acs.nanolett.6b0033110.1021/acs.nanolett.6b00331 ↗
45. 10.1016/j.cis.2017.02.00910.1016/j.cis.2017.02.009 ↗
46. 10.3390/molecules2514315910.3390/molecules25143159 ↗
47. 10.1016/j.nantod.2019.10079510.1016/j.nantod.2019.100795 ↗
48. 10.7150/thno.4256410.7150/thno.42564 ↗
49. 10.1038/nnano.2007.26010.1038/nnano.2007.260 ↗
50. 10.7150/thno.1154410.7150/thno.11544 ↗
51. 10.1016/j.biomaterials.2019.02.02610.1016/j.biomaterials.2019.02.026 ↗
52. 10.1039/c2nr32070c10.1039/c2nr32070c ↗
53. 10.1039/C9NR03353J10.1039/C9NR03353J ↗
54. 10.1111/hdi.1256010.1111/hdi.12560 ↗
55. 10.3390/ijms2206316110.3390/ijms22063161 ↗
56. 10.1016/j.celrep.2017.12.07710.1016/j.celrep.2017.12.077 ↗
57. 10.1146/annurev-cancerbio-030518-05584410.1146/annurev-cancerbio-030518-055844 ↗
58. 10.1038/s41418-020-0528-x10.1038/s41418-020-0528-x ↗
59. 10.1038/onc.2015.3210.1038/onc.2015.32 ↗
60. 10.1002/nbm.97010.1002/nbm.970 ↗
61. 10.1002/smll.20100076310.1002/smll.201000763 ↗
62. 10.1148/radiol.244206059910.1148/radiol.2442060599 ↗
63. 10.1111/jcmm.1300810.1111/jcmm.13008 ↗
64. 10.1038/nchembio.141610.1038/nchembio.1416 ↗
65. 10.1083/jcb.20060503810.1083/jcb.200605038 ↗
66. 10.1038/nature0589410.1038/nature05894 ↗
67. 10.1164/rccm.201102-0271OC10.1164/rccm.201102-0271OC ↗
68. 10.1105/tpc.18.0053510.1105/tpc.18.00535 ↗
69. 10.3390/ijms2121838710.3390/ijms21218387 ↗
70. 10.3390/ijms2118675110.3390/ijms21186751 ↗
71. 10.2353/ajpath.2010.09024910.2353/ajpath.2010.090249 ↗
72. 10.1096/fj.201902278RR10.1096/fj.201902278RR ↗
73. 10.1016/j.phymed.2020.15337010.1016/j.phymed.2020.153370 ↗
74. 10.1038/s41418-022-00943-y10.1038/s41418-022-00943-y ↗
75. 10.1038/s41418-019-0338-110.1038/s41418-019-0338-1 ↗
76. 10.1016/j.cell.2012.04.02610.1016/j.cell.2012.04.026 ↗
77. 10.1155/2021/178348510.1155/2021/1783485 ↗
78. 10.3390/cancers1201013810.3390/cancers12010138 ↗
79. 10.1021/acsami.5b0574410.1021/acsami.5b05744 ↗
80. 10.1016/j.biomaterials.2014.04.00910.1016/j.biomaterials.2014.04.009 ↗
81. 10.1021/mp800051m10.1021/mp800051m ↗
82. 10.1021/acsabm.2c0006810.1021/acsabm.2c00068 ↗
83. 10.1021/acsnano.1c0038010.1021/acsnano.1c00380 ↗